Company news

Black Diamond Therapeutics, Inc. news in 2025

Black Diamond Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

December 3, 2025

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

December 2, 2025

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 6, 2025

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 6, 2025

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2025

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 29, 2025

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

March 19, 2025

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 6, 2025

Decks in 2025